Can a targeted drug plus immunotherapy outsmart tough breast cancer?
NCT ID NCT07729956
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This phase III trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy (PD-1 antibody), works better than standard chemotherapy plus immunotherapy for people with advanced triple-negative breast cancer that has a specific protein (PD-L1). The study includes about 436 participants who have not received prior treatment for their advanced cancer. Researchers are measuring how long the cancer stays under control and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-B01D1 (a drug that targets cancer cells) plus a PD-1 antibody (immunotherapy)
- What this could lead to
- If successful, this could offer a more effective first-line treatment option for people with advanced triple-negative breast cancer that expresses PD-L1.
- What could go wrong
- This is an early-phase trial, so the new combination may not prove better than the standard treatment. Side effects from the experimental drug are not yet fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
- Can a drug combo outsmart a tough breast cancer subtype?
- Can a new drug combo outsmart triple-negative breast cancer?
- Can your own immune cells fight advanced cancer?
- Can a biomarker spare breast cancer patients from harsh chemo?